AT Bancorp’s Alexion Pharmaceuticals ALXN Stock Holding History

AT Bancorp’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$1.04M	Sell	7,694 -82	-1%	-$10.2K	0.13%	96
2018 Q4	$757K	Buy	7,776 +1,462	+23%	+$173K	0.1%	111
2018 Q3	$877K	Sell	6,314 -2,346	-27%	-$294K	0.09%	113
2018 Q2	$1.07M	Sell	8,660 -5,789	-40%	-$677K	0.12%	99
2018 Q1	$1.61M	Buy	14,449 +792	+6%	+$94.7K	0.17%	72
2017 Q4	$1.63M	Buy	13,657 +8,813	+182%	+$1.07M	0.18%	73
2017 Q3	$679K	Buy	4,844 +981	+25%	+$133K	0.08%	125
2017 Q2	$470K	Sell	3,863 -4,671	-55%	-$544K	0.06%	165
2017 Q1	$3.09M	Buy	+8,534	New	+$1.1M	0.4%	47
2016 Q4	–	Sell	-8,992	Closed	-$1.1M	–	268
2016 Q3	$1.1M	Buy	+8,992	New	+$1.16M	0.15%	147

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AT Bancorp's ALXN Position: Q1 2019 in Review

AT Bancorp reduced its Alexion Pharmaceuticals (ALXN) stake by 1.1% in Q1 2019, selling an estimated $10.2K and leaving 7,694 shares worth $1.04M. The position accounts for 0.13% of the portfolio, ranked #96.

AT Bancorp first reported a position in ALXN in Q3 2016 and has held it in 10 quarters since. The position peaked at $3.09M in Q1 2017. 611 funds tracked by Wall St. Rank hold ALXN as of Q1 2019.

AT Bancorp held 7,694 shares of Alexion Pharmaceuticals worth $1.04M as of Q1 2019.
AT Bancorp sold 82 Alexion Pharmaceuticals shares in Q1 2019, an estimated $10.2K.
Alexion Pharmaceuticals made up 0.13% of AT Bancorp's portfolio in Q1 2019, its #96 holding.
AT Bancorp first reported a position in Alexion Pharmaceuticals in Q3 2016 and has held it in 10 quarters since.
AT Bancorp's Alexion Pharmaceuticals position peaked at $3.09M in Q1 2017.
611 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2019.

Based on AT Bancorp's 13F filing for Q1 2019, filed 13 May 2019.